FORM PTO-1449



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. SERIAL NO. 109904-00015 09/786,361

APPLICANT

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

GRASS, et al.

FILING DATE GROUP

March 14, 2001 1627

	ļ	Gomeni, R., "Pharm-an Interactive Graphic Program for Individual and Population Pharmacokinetic Parameter Estimation", Comput. Bio. Med. (1994) Vol. 14, No. 1, pp 25-34		
	BY	Parameter Estimation , Comput. Bio. Med. (1994) Vol. 14, No. 1, pp 20-04		
	BZ	Hampton et al., "Comparison of MS-DOS and Macintosh Pharmacokinetic Analysis Programs Using a Two-Compartment, Two-Infusion Dosing Scheme", Clinical Pharmacy (1991) Vol. 10, pp. 206-209		
	CA	Hayashi et al., "Pharmacokinetic Analysis of Cimetidine Plasma Concentration Data in Dogs Using a Two Phase Absorption Model", <u>Pharmaceutical Research</u> (1994) Vol. 11, No. 10, page S-420		
	СВ	Hoang, K.T., "Physiologically Based Pharmacokinetic Models: Mathematical Fundamentals and Simulation Implementations", <u>Toxicology Letters</u> (1995) Vol. 79, pp. 99-106		
	СС	Idkaidek et al., "Determination of the Population Pharmacokinetic Parameters of Sustained-Release and Enteric-Coated Oral Formulations, and the Suppository Formulation of Diclofenac Sodium by Simultaneous Data Fitting Using MONMEM", Biopharmaceutics & Drug Disposition (1998) Vol. 19, pp. 169-174		
	CD	Jelliffe, R.W., "The USC*PACK PC Programs for Population Pharmacokinetic Modeling, Modeling of Large Kinetic/Dynamic Systems, and Adaptive Control of Drug Dosage Regimens" Symposium on Computer Applications in Medical Care: A Conference of the American Medical Informatics Association (1991) pp. 922-923		
_	E	Kalmaz, E.E., "Computer Modeling and Parameter Estimation for Pharmacokinetics and Toxicity Studies", Journal of American College of Toxicology (1996) Vol. 5, No. 6, page 607		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	CF	Keller et al., "Standardized Structure and Modular Design of a Pharmacokinetic Database", Computer Methods and Programs in Biomedicine (1988) Vol. 55, pp. 107-115		
	es	Kirkup et al., "A Demonstration of Pharmacokinetics and Physiological Modelling Using a Microcomputer for Data Capture and Analysis", Computer Applications in the Biosciences (1986) Vol. 2, No. 4, pp. 277-282		
	СН	Kwon et al., "Theoretical Considerations on Two Equations for Estimating the Extent of Absorption After Oral Administration of Drugs", Pharmaceutical Research (1986) Vol. 13, No. 4, pp. 566-569		
EXAMINE	:R	DATE CONSIDERED		

conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 7 of 16

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

SERIAL NO. ATTY. DOCKET NO. 109904-00015 09/786,361 APPLICANT

LIST OF REFE CES CITED BY APPLICANT

(Use several sheets if necessary)

GRASS, et al.				
ILING DATE	GROUP			
March 14, 2001	1627			


285682_1.DOC

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CI	Langguth et al., "Variable Gastric Emptying and Discontinuities in Drug Absorption Profiles: Dependence of Rates and Extent of Cimetidine Absorption on Motility Phase and PH", Biopharmaceutics & Drug Disposition (1994) Vol. 15, pp. 719-746			
СЈ	Leader et al., "Integrating Pharmacokinetics into Point-of-Care Information Systems", Clinical Pharmacokinetics (1996) Vol. 31, No. 3, pp. 165-173			
ск	Leahy et al., "Physiologic Based Pharmacokinetic Modelling and QSAR", <u>Bioactive Compound Design:</u> Possibilities for Industrial Use, pp. 147-151, 1996			
CL	Lincoln et al., "Pharmacokinetic Simulation: A Future Means for Better Centrol of Cancer Chemotherapy", Recent Results in Cancer Research, pp. 103-107			
CM	Lu et al., "An Interactive Program for Pharmacokinetic Modeling", <u>Journal of Pharmaceutical Sciences</u> (1993) Vol. 82, No. 5, pp. 537-542			
CN	Luner et al., "Description and Simulation of a Multiple Mixing Tank Model to Predict the Effect of Bile Sequestrants on Bile Salt Excretion", Journal of Pharmaceutical Sciences (1993) Vol. 82, No. 3, pp. 311-318			
со	Mazumdar et al., "A Mathematical Study of Simple Exponential Modelling in Biochemical Processes", Australasian Physical & Engineering Sciences in Medicine (1991) Vol. 14, No. 4, pp. 226-233			
СР	Metzler et al., "Package of Computer Programs for Pharmacokinetic Modeling", <u>Biometrics, Journal of the Biometric Society</u> (1974) Vol. 30, No. 3, pp. 562-563			
cq	Metzler, C.M. "Commentary to 'Linear and Nonlinear System Approaches in Pharmacokinetics. How Much Do They Have To Offer? II. The Response Mapping Operator (RMO) Approach", <u>J. Pharmacokin, Biopharm</u> , (1988) Vol. 16, pp. 543-571			
CR	Murata et al., "Pharmacokinetic Analysis of Single or Multiple-Dose Plasma Drug Concentration Data with a Microcomputer Using Multi-Fraction Absorption Models", Journal of Pharmaceutical Sciences (1989) Vol. 78, No. 2, pp. 154-159			
EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

20

25



6. A method of determining levels of intracellular function of glutathione and analyzing biochemically cellular antioxidant function in an individual comprising the steps of:

inoculating the cell culture medium of claim 1 with lymphocytes from said individual;

incubating the inoculated cell culture medium; and comparing the response of the lymphocytes with an average response of lymphocytes from a control group of individuals.

7. A cell cuture medium useful for determining levels of intracellular function of cysteine and performing biochemical analysis of antioxidant function in human lymphocytes, said medium comprising:

a buffered, serum-free solution containing the following ingredients:

a carbohydrate selected from the group consisting of glucose and a compound biologically capable of producing glucose in said lymphocytes,

W.

a biologically usable form of pantothenic acid, choline or a biological usable form of a substance capable of producing choline in said lymphocytes,

inorganic ions comprising chloride, phosphate, calcium, magnesium, potassium, sodium, and iron in a biologically utilizable form,

cumene hydroperoxide,

deionized water,

N-Acetyl-L-Cysteine, and

a mitogen in an amount effective to stimulate said lymphocytes being assayed;

said buffered, serum-free solution having a pH from about 6.8 to 7.6,

said cell culture medium characterized by being effective to determine nutritional deficiencies, inadequacies, and imbalances and to biochemically analyze antioxidant function of the lymphocytes.

8. The cell cuture medium of claim 7, wherein said medium is supplemented with a nutrient supplement selected from the group consisting of biological utilizable forms of amino acids and vitamins, the nutrient being tested for being omitted from or being present in limiting or inhibitory amounts in the nutrient supplement.

HOOLYOHD : HITH

20

5

9. The cell cuture medium of claim 7, wherein said vitamins are selected from the group consisting of biotin, folinic acid or a biologically usable form of folic acid, nicotinamide or nicotinic acid, riboflavin, thiamin, vitamin B₆, and vitamin B₁₂, and compounds capable of producing them in the cells; and wherein said amino acids or the compounds biologically capable of producing the amino acids comprise L-arginine, L-cysteine, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine, the amino acids being present as a group, each in an amount not exceeding inhibitory concentrations.

10. The cell cuture medium of claim 7, wherein said cumene hydroperoxide is present in a concentration of from about 50 μM .

11. The cell culture medium of claim 7, wherein the cell culture medium is supplemented at concentrations eliciting approximately a maximal response with one or more stimulatory nutrients selected from the goup consisting of pyruvate, adenine, and inositol or compounds capable of producing them within said lymphocytes.